retinal degenerative diseases

Nanoscope Therapeutics Appoints New Chief Medical Officer

by | Apr 26, 2024
Dallas-based Nanoscope said Dr. Allen C. Ho will help define the strategy of developing its gene mutation-agnostic therapies. Ho is attending surgeon and director of retina research at Wills Eye Hospital and co-director of the Wills Eye Hospital Retina Service.
MORE
Nanoscope Therapeutics Bolsters Board with Addition of Ophthalmic Veteran as Strategic Adviser
by | Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE
Nanoscope Therapeutics Names New Vice President of Quality
by | Jan 11, 2023

Nanoscope Therapeutics Inc., a Dallas-based clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, has appointed Massoud Motamed, Ph.D., as vice president of quality.

Motamed brings nearly a decade of CGMP quality and compliance experience, including extensive experience in manufacturing and regulatory review of gene therapy products....

MORE